Location History:
- Neuried, DE (2009)
- Muenchen, DE (2010)
- Munich, DE (2004 - 2011)
Company Filing History:
Years Active: 2004-2011
Title: Innovations and Contributions of Inventor Johannes Bange
Introduction
Johannes Bange is a notable inventor based in Munich, Germany. He has made significant contributions to the field of medical diagnostics and treatment, particularly concerning receptor tyrosine kinase (RTK) hyperfunction-induced disorders. With a total of 5 patents to his name, Bange's work has the potential to impact cancer treatment and genetic diagnostics.
Latest Patents
One of Bange's latest patents is a method of diagnosing an RTK-hyperfunction-induced disorder. This invention provides a method for identifying a genetic predisposition to such disorders in mammals. The method involves determining the presence of a nucleic acid that encodes a mutated fibroblast growth factor receptor-4 (FGFR-4) protein in a nucleic acid sample. The presence of this mutated nucleic acid indicates a potential RTK-hyperfunction-induced disorder.
Another significant patent focuses on the use of inhibitors for treating RTK-hyperfunction-induced disorders, particularly cancer. This invention outlines a therapeutic method for treating cancer in mammals that possess a mutated FGFR-4 protein. The method includes administering an effective amount of at least one inhibitor targeting the mutated FGFR-4, which contains specific point mutations in its transmembrane domain.
Career Highlights
Johannes Bange is affiliated with the Max Planck Society for the Advancement of Science, where he conducts his research and development. His work is characterized by a strong focus on innovative solutions for complex medical challenges. Bange's contributions have been recognized within the scientific community, and his patents reflect his commitment to advancing medical science.
Collaborations
Bange has collaborated with esteemed colleagues such as Axel Ullrich and Pjotr Knyazev. These partnerships have likely enhanced the depth and impact of his research, fostering an environment of innovation and discovery.
Conclusion
Johannes Bange's work exemplifies the intersection of innovation and medical science. His patents not only contribute to the understanding of RTK-hyperfunction-induced disorders but also pave the way for new therapeutic approaches in cancer treatment. Bange's ongoing research continues to hold promise for future advancements in the field.